Thermo Fisher reported stronger‑than‑expected Q4 results and gave 2026 guidance calling for roughly 4–6% revenue growth, driven by life‑science solutions and laboratory products. The company posted a double‑digit increase in life‑science solutions and reiterated capital‑intensive investments to support customers in biologics, clinical research, and diagnostics. Thermo Fisher’s guidance signals steady demand for lab consumables, instruments, and biopharma services as developers scale discovery and manufacturing. The forecasted growth and margin expectations will influence supplier planning across the industry, affecting reagent supply chains and instrument placements for diagnostic and research customers.